Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) EBIT (2020 - 2025)

Historic EBIT for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $22.9 million.

  • Pharming's EBIT rose 45664.56% to $22.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 12972.94%. This contributed to the annual value of -$8.6 million for FY2024, which is 6003.34% down from last year.
  • Per Pharming's latest filing, its EBIT stood at $22.9 million for Q3 2025, which was up 45664.56% from $3.8 million recorded in Q2 2025.
  • Over the past 5 years, Pharming's EBIT peaked at $6.3 billion during Q1 2021, and registered a low of -$6.2 billion during Q2 2021.
  • Over the past 5 years, Pharming's median EBIT value was -$3.5 million (recorded in 2021), while the average stood at -$100433.5.
  • Per our database at Business Quant, Pharming's EBIT soared by 56480.42% in 2022 and then crashed by 14698.88% in 2023.
  • Pharming's EBIT (Quarter) stood at -$14.6 million in 2021, then skyrocketed by 30.27% to -$10.2 million in 2022, then skyrocketed by 47.19% to -$5.4 million in 2023, then crashed by 60.03% to -$8.6 million in 2024, then soared by 365.25% to $22.9 million in 2025.
  • Its last three reported values are $22.9 million in Q3 2025, $3.8 million for Q2 2025, and -$7.0 million during Q1 2025.